Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients-Reference-Cited by-同舟云学术

Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients

Published:2014-12-09 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Ballinger Angela E¹,Palmer Suetonia C¹,Nistor Ionut²³,Craig Jonathan C⁴⁵,Strippoli Giovanni FM⁴⁵⁶⁷⁸

Affiliation:

1. University of Otago Christchurch; Department of Medicine; 2 Riccarton Ave Christchurch New Zealand 8041

2. "Gr. T. Popa" University of Medicine and Pharmacy; Nephrology Department; Bdul Carol I, No 50 Iasi Iasi Romania 700503

3. Ghent University Hospital; European Renal Best Practice Methods Support Team; Ghent Belgium

4. The University of Sydney; Sydney School of Public Health; Edward Ford Building A27 Sydney NSW Australia 2006

5. The Children's Hospital at Westmead; Cochrane Renal Group, Centre for Kidney Research; Westmead NSW Australia 2145

6. University of Bari; Department of Emergency and Organ Transplantation; Bari Italy 70100

7. Mario Negri Sud Consortium; Department of Clinical Pharmacology and Epidemiology; Santa Maria Imbaro Italy

8. Diaverum; Medical-Scientific Office; Lund Sweden. Amedeo Avogadro University of Eastern Piedmont; Division of Nephrology and Transplantation, Department of Translational Medicine; Novara Italy 28100

Publisher

Wiley

Subject

Pharmacology (medical)

Reference163 articles.

1. Assessing the use of the calcimimetic cinacalcet with low dose vitamin D versus escalating doses of vitamin D alone in the treatment of secondary hyperparathyroidism (HPT) - The ACHIEVE Study [abstract no: 39];Charytan;American Journal of Kidney Diseases,2007

2. Efficacy of treatments targeting the calcium-sensing receptor (CaR) and vitamin D receptor (VDR) in controlling parathyroid hormone (PTH) in hemodialysis (HD) patients: cinacalcet HCI plus low-dose vitamin D vs flexible vitamin D alone [abstract no: SU-PO812];Charytan;Journal of the American Society of Nephrology,2007

3. A comparison of cinacalcet HCI and low-dose vitamin D vs escalating doses of vitamin D alone - the ACHIEVE study [abstract no: PUB354];Fishbane;Journal of the American Society of Nephrology,2006

4. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results;Fishbane;Clinical Journal of The American Society of Nephrology: CJASN,2008

5. Cinacalcet with low dose vitamin D provides improved control of parathyroid hormone, calcium, and calcium-phosphorus product in hemodialysis patients with secondary hyperparathyroidism compared with vitamin D alone [abstract no: SaP383];Fishbane;Nephrology Dialysis Transplantation,2007

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of cinacalcet in children and adolescents with chronic kidney disease-mineral bone disorder: systematic review and proportional meta-analysis of case series;International Urology and Nephrology;2023-11-15

2. Novel Approaches in Chronic Renal Failure without Renal Replacement Therapy: A Review;Biomedicines;2023-10-18

3. Efficacy and Safety of Upacicalcet in Hemodialysis Patients with Secondary Hyperparathyroidism;Clinical Journal of the American Society of Nephrology;2023-09-11

4. Brown Tumour in Chronic Kidney Disease: Revisiting an Old Disease with a New Perspective;Cancers;2023-08-15

5. Risk factors of recurrent secondary hyperparathyroidism after adequate primary surgical treatment;Frontiers in Endocrinology;2023-02-03